{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:37:03Z","timestamp":1768534623221,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bbmt.2020.07.010","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T02:11:26Z","timestamp":1594951886000},"page":"2027-2033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel Approach for Bone Marrow Transplantation Conditioning in Acute Myelogenous Leukemia not Responding to the Induction Therapy Using Etoposide Carried in Lipid Core Nanoparticles: A Pilot Clinical Study"],"prefix":"10.1016","volume":"26","author":[{"given":"Sandra S.","family":"Rohr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul C.","family":"Maranh\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thauany M.","family":"Tavoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra T.","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsy","family":"Areco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora F.","family":"Deus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 S.R.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.07.010_bib0001","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/bmt.2017.8","article-title":"Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy","volume":"52","author":"Gyurkocza","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0002","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.1988.6.4.576","article-title":"High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia","volume":"6","author":"Riddell","year":"1988","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2020.07.010_bib0003","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/2.suppl_1.47","article-title":"The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data","volume":"2","author":"Horning","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0004","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0005","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1080\/10428190412331283206","article-title":"Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML","volume":"45","author":"Scott","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0006","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0007","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/17425247.2017.1276560","article-title":"Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents","volume":"14","author":"Maranh\u00e3o","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0008","first-page":"1003","article-title":"Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia: a possible new strategy for the treatment of the disease","volume":"25","author":"Maranh\u00e3o","year":"1992","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0009","first-page":"4660","article-title":"Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia","volume":"54","author":"Maranh\u00e3o","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0010","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood.V52.6.1099.1099","article-title":"Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells","volume":"52","author":"Ho","year":"1978","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00280-006-0252-3","article-title":"Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers","volume":"59","author":"Dias","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0012","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-008-0738-2","article-title":"Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study","volume":"63","author":"Pires","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0013","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00280-005-0090-8","article-title":"Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE","volume":"57","author":"Pinheiro","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0014","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2004.12.015","article-title":"Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma","volume":"97","author":"Azevedo","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-002-0437-3","article-title":"Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients","volume":"49","author":"Maranh\u00e3o","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00280-003-0692-y","article-title":"Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease","volume":"53","author":"Hungria","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF02985191","article-title":"cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia","volume":"6","author":"Amsacrine","year":"1989","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0018","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428199809092687","article-title":"Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group","volume":"28","author":"Bishop","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0019","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-012-1990-z","article-title":"High-dose etoposide in allogeneic stem cell transplantation","volume":"70","author":"Bruserud","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0020","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0021","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0022","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","article-title":"The use of the nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma","volume":"1","author":"Karnofsky","year":"1948","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0023","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0024","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). Version 5.0. November 27, 2017."},{"key":"10.1016\/j.bbmt.2020.07.010_bib0025","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1053\/bbmt.2002.v8.abbmt080656","article-title":"Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants","volume":"8","author":"Bacigalupo","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0026","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0027","series-title":"ESH-EBMT Handbook on Haemopoietic Stem Cell Transplantation","year":"2012"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0028","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1182\/blood.V128.22.5802.5802","article-title":"Evaluation of endothelial damage in sinusoidal obstructive syndrome","volume":"128","author":"Butta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0029","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0030","series-title":"Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation","year":"2015"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0031","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0032","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1211\/0022357022232","article-title":"Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide","volume":"55","author":"Valduga","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0033","series-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0034","unstructured":"IBM Corp.IBM SPSS Statistics for Windows, Version 22.0. Released 2013.Armonk, NY: IBM Corp."},{"key":"10.1016\/j.bbmt.2020.07.010_bib0035","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1182\/blood.V69.4.1015.1015","article-title":"Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies","volume":"69","author":"Blume","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0036","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1182\/blood.V72.5.1567.1567","article-title":"Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias","volume":"72","author":"Schmitz","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0037","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood.V81.8.2187.2187","article-title":"A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study","volume":"81","author":"Blume","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0038","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood.V82.9.2920.2920","article-title":"Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission","volume":"82","author":"Snyder","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0039","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.bmt.1702519","article-title":"Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience","volume":"26","author":"Sierra","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0040","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","article-title":"A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission","volume":"12","author":"Marks","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0041","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"Nagler","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0042","first-page":"2297","article-title":"Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions","volume":"6","author":"Tavares","year":"2011","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0043","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0044","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0045","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","article-title":"Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation","volume":"11","author":"Wong","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0046","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-013-1774-5","article-title":"Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia","volume":"92","author":"Schneidawind","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0047","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3026(15)00146-5","article-title":"Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis","volume":"2","author":"Nagler","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0048","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bbmt.2003.08.004","article-title":"A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome","volume":"9","author":"Fung","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.010_bib0049","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:43Z","timestamp":1761059623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120304432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1083879120304432"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.010","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Approach for Bone Marrow Transplantation Conditioning in Acute Myelogenous Leukemia not Responding to the Induction Therapy Using Etoposide Carried in Lipid Core Nanoparticles: A Pilot Clinical Study","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}